Muhammad Hamza Shah

Mr. Muhammad Hamza Shah

School of Medicine, Queen's University Belfast, Belfast, UK
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in World Neurosurgery
Verified
Journal Article
Open access
WAWireko Andrew Awuah
Wireko Andrew Awuah
AAArjun Ahluwalia
Arjun Ahluwalia
KDKwadwo Darko
Kwadwo Darko
VSVivek Sanker
Vivek Sanker
JTJoecelyn Kirani Tan
Joecelyn Kirani Tan
Oday AtallahOday Atallah
Oday Atallah
Brain-computer interfaces (BCIs), a remarkable technological advancement in neurology and neurosurgery, mark a significant leap since the inception of electroencephalography in 1924. These interfaces effectively convert central nervous system signals into commands for external devices, offering revolutionary benefits to patients with severe communication and motor impairments due to a myriad of neurological conditions like stroke, spinal cord injuries, and neurodegenerative disorders. BCIs enable these individuals to communicate and interact with their environment, using their brain signals to operate interfaces for communication and environmental control. This technology is especially crucial for those completely locked in, providing a communication lifeline where other methods fall short. The advantages of BCIs are profound, offering autonomy and an improved quality of life for patients with severe disabilities. They allow for direct interaction with various devices and prostheses, bypassing damaged or nonfunctional neural pathways. However, challenges persist, including the complexity of accurately interpreting brain signals, the need for individual calibration, and ensuring reliable, long-term use. Additionally, ethical considerations arise regarding autonomy, consent, and the potential for dependence on technology. Despite these challenges, BCIs represent a transformative development in neurotechnology, promising enhanced patient outcomes and a deeper understanding of brain-machine interfaces.

4 September 2024 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
AMAdele Mazzoleni
Adele Mazzoleni
WAWireko Andrew Awuah
Wireko Andrew Awuah
VSVivek Sanker
Vivek Sanker
HBHareesha Rishab Bharadwaj
Hareesha Rishab Bharadwaj
NANicholas Aderinto
Nicholas Aderinto
MPMarios Papadakis
Marios Papadakis
Chromosomal instability (CIN) is a pivotal factor in gliomas, contributing to their complexity, progression, and therapeutic challenges. CIN, characterized by frequent genomic alterations during mitosis, leads to genetic abnormalities and impacts cellular functions. This instability results from various factors, including replication errors and toxic compounds. While CIN’s role is well documented in cancers like ovarian cancer, its implications for gliomas are increasingly recognized. CIN influences glioma progression by affecting key oncological pathways, such as tumor suppressor genes (e.g., TP53), oncogenes (e.g., EGFR), and DNA repair mechanisms. It drives tumor evolution, promotes inflammatory signaling, and affects immune interactions, potentially leading to poor clinical outcomes and treatment resistance. This review examines CIN’s impact on gliomas through a narrative approach, analyzing data from PubMed/Medline, EMBASE, the Cochrane Library, and Scopus. It highlights CIN’s role across glioma subtypes, from adult glioblastomas and astrocytomas to pediatric oligodendrogliomas and astrocytomas. Key findings include CIN’s effect on tumor heterogeneity and its potential as a biomarker for early detection and monitoring. Emerging therapies targeting CIN, such as those modulating tumor mutation burden and DNA damage response pathways, show promise but face challenges. The review underscores the need for integrated therapeutic strategies and improved bioinformatics tools like CINdex to advance understanding and treatment of gliomas. Future research should focus on combining CIN-targeted therapies with immune modulation and personalized medicine to enhance patient outcomes.

23 October 2024 in Health Science Reports
Verified
Journal Article
Open access
WAWireko Andrew Awuah
Wireko Andrew Awuah
JTJoecelyn Kirani Tan
Joecelyn Kirani Tan
MSMuhammad Hamza Shah
Muhammad Hamza Shah
AAArjun Ahluwalia
Arjun Ahluwalia
SRSakshi Roy
Sakshi Roy
DODenys Ovechkin
Denys Ovechkin
Introduction: The prevalence of abdominal injuries in war and conflict zones, particularly in low‐ and middle‐income countries (LMICs), presents a significant healthcare challenge. These injuries, often resulting from explosive devices, firearms, and shrapnel, lead to high morbidity and mortality rates due to delayed diagnoses, inadequate medical infrastructure, and limited access to specialised care. This review aims to summarise the literature on conflict‐related abdominal injuries in LMICs, highlighting the impact of such trauma on healthcare systems and patient outcomes, and suggesting strategies for improvement.Methods: A comprehensive narrative review was conducted, focusing on studies from contemporary and historical conflict‐ridden nations. Databases such as PubMed, EMBASE, Google Scholar, the Cochrane Library, and Scopus were searched using specific keywords. Inclusion criteria encompassed various study designs and both paediatric and adult populations, with studies providing raw data prioritised. Exclusions included non‐English articles, non‐peer‐reviewed studies, and those not reporting outcomes or involving high‐income countries.Results: The review identified significant challenges in managing war‐related abdominal trauma in LMICs, including a shortage of healthcare personnel and infrastructure, socio‐political barriers, and research gaps. Clinical implications of such injuries include elevated mortality rates, with surgical and nonsurgical management outcomes varying significantly. Positive advancements in diagnostics and surgical techniques have improved survival rates, yet the need for further infrastructural and workforce enhancements remains critical.Conclusion: Abdominal trauma in conflict‐affected LMICs necessitates focused efforts to improve healthcare delivery, including targeted funding for infrastructure and equipment, development of training programs for trauma specialists, and increased humanitarian aid. Bridging research gaps and fostering collaborative efforts are essential for advancing the management of abdominal trauma and enhancing patient outcomes in these challenging environments.

30 July 2024 in Health Science Reports
Verified
Journal Article
Open access
WAWireko A. Awuah
Wireko A. Awuah
JTJoecelyn K. Tan
Joecelyn K. Tan
HBHareesha Rishab Bharadwaj
Hareesha Rishab Bharadwaj
NANicholas Aderinto
Nicholas Aderinto
TFTomas Ferreira
Tomas Ferreira
OAOday Atallah
Oday Atallah
Background and aims: In low‐ and middle‐income countries (LMICs), a shortage of skilled surgical practitioners hampers healthcare delivery, impacting well‐being and economic growth. Surgical mentorship programs offer a promising solution but face challenges in implementation. This review aims to comprehensively assess the impact of surgical mentorship programs in LMICs and identify challenges and opportunities for their development and implementation.Methods: A thorough literature search was conducted from 2000 to 2023 using multiple databases, focusing on surgical mentorship programs in LMICs. Inclusion criteria encompassed full‐text articles in English that demonstrated characteristics of mentorship. Rigorous exclusion criteria were applied to ensure high‐quality evidence inclusion.Results: Surgical mentorship programs in LMICs strengthen local surgical capacity, improve surgical skills and patient outcomes, optimize resources and technology utilization, and positively impact medical students aspiring to be surgeons. However, challenges such as resistance to change, resource limitations, financial constraints, logistical and technological challenges, and time constraints hinder their implementation.Conclusion: Despite challenges, surgical mentorship programs hold promise for enhancing surgical capacity and healthcare quality in LMICs. Standardized metrics for accountability, innovative funding mechanisms, collaborative partnerships for scalability, interdisciplinary integration, and leveraging virtual mentorship programs are key strategies to overcome challenges and foster sustainable learning cultures, ultimately contributing to improved healthcare equity and quality in low‐resource settings.

19 September 2024 in Brain Research
Verified
Journal Article
Open access
WAWireko Andrew Awuah
Wireko Andrew Awuah
ABAdam Ben-Jaafar
Adam Ben-Jaafar
JKJonathan Sing Huk Kong
Jonathan Sing Huk Kong
VSVivek Sanker
Vivek Sanker
MSMuhammad Hamza Shah
Muhammad Hamza Shah
OAOday Atallah
Oday Atallah
Cerebrovascular diseases (CVDs) include conditions such as stroke, cerebral amyloid angiopathy (CAA) and cerebral small vessel disease (CSVD), which contribute significantly to global morbidity and healthcare burden. The pathophysiology of CVD is complex, involving inflammatory, cellular and vascular mechanisms. Recently, research has focused on triggering receptor expressed on myeloid cells 2 (TREM2), an immune receptor predominantly found on microglia. TREM2 interacts with multiple signalling pathways, particularly toll-like receptor 4 (TLR4) and nuclear factor kappa B (NF-κB), inhibiting patients' inflammatory response. This receptor plays an essential role in both immune regulation and neuroprotection. TREM2 deficiency or dysfunction is associated with impaired microglial responses, exacerbated neurodegeneration and neuroinflammation. Up until recently, TREM2 related studies have focused on neurodegenerative diseases (NDs), however a shift in focus towards CVDs is beginning to take place. Advancements in CVD research have focused on developing therapeutic strategies targeting TREM2 to enhance recovery and reduce long-term deficits. These include the exploration of TREM2 agonists and combination therapies with other anti-inflammatory agents, which may synergistically reduce neuroinflammation and promote neuroprotection. The modulation of TREM2 activity holds potential for innovative treatment approaches aimed at improving patient outcomes following cerebrovascular insults. This review compiles current research on TREM2, emphasising its molecular mechanisms, therapeutic potential, and advancements in CNS disease research.

30 August 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
WAWireko Andrew Awuah
Wireko Andrew Awuah
MSMuhammad Hamza Shah
Muhammad Hamza Shah
JTJoecelyn Kirani Tan
Joecelyn Kirani Tan
SRSruthi Ranganathan
Sruthi Ranganathan
VSVivek Sanker
Vivek Sanker
OAOday Atallah
Oday Atallah
Background: Gliomas, particularly glioblastoma multiforme (GBM), are highly aggressive brain tumors that present significant challenges in oncology due to their rapid progression and resistance to conventional therapies. Despite advancements in treatment, the prognosis for patients with GBM remains poor, necessitating the exploration of novel therapeutic approaches. One such emerging strategy is the development of glioma vaccines, which aim to stimulate the immune system to target and destroy tumor cells.Aims: This review aims to provide a comprehensive evaluation of the current landscape of glioma vaccine development, analyzing the types of vaccines under investigation, the outcomes of clinical trials, and the challenges and opportunities associated with their implementation. The goal is to highlight the potential of glioma vaccines in advancing more effective and personalized treatments for glioma patients.Materials and Methods: This narrative review systematically assessed the role of glioma vaccines by including full‐text articles published between 2000 and 2024 in English. Databases such as PubMed/MEDLINE, EMBASE, the Cochrane Library, and Scopus were searched using key terms like “glioma,” “brain tumor,” “glioblastoma,” “vaccine,” and “immunotherapy.” The review incorporated both pre‐clinical and clinical studies, including descriptive studies, animal‐model studies, cohort studies, and observational studies. Exclusion criteria were applied to omit abstracts, case reports, posters, and non‐peer‐reviewed studies, ensuring the inclusion of high‐quality evidence.Results: Clinical trials investigating various glioma vaccines, including peptide‐based, DNA/RNA‐based, whole‐cell, and dendritic‐cell vaccines, have shown promising results. These vaccines demonstrated potential in extending survival rates and managing adverse events in glioma patients. However, significant challenges remain, such as therapeutic resistance due to tumor heterogeneity and immune evasion mechanisms. Moreover, the lack of standardized guidelines for evaluating vaccine responses and issues related to ethical considerations, regulatory hurdles, and vaccine acceptance among patients further complicate the implementation of glioma vaccines.Discussion: Addressing the challenges associated with glioma vaccines involves exploring combination therapies, targeted approaches, and personalized medicine. Combining vaccines with traditional therapies like radiotherapy or chemotherapy may enhance efficacy by boosting the immune system’s ability to fight tumor cells. Personalized vaccines tailored to individual patient profiles present an opportunity for improved outcomes. Furthermore, global collaboration and equitable distribution are critical for ensuring access to glioma vaccines, especially in low‐ and middle‐income countries with limited healthcare resourcesConclusion: Glioma vaccines represent a promising avenue in the fight against gliomas, offering hope for improving patient outcomes in a disease that is notoriously difficult to treat. Despite the challenges, continued research and the development of innovative strategies, including combination therapies and personalized approaches, are essential for overcoming current barriers and transforming the treatment landscape for glioma patients.